

1. Record Nr.	UNINA9910460278403321
Autore	Li Jie Jack
Titolo	Top drugs : history, pharmacology, syntheses // Jie Jack Li
Pubbl/distr/stampa	New York, New York : , : Oxford University Press, , 2015 ©2015
ISBN	0-19-756291-4 0-19-936260-2 0-19-936259-9
Descrizione fisica	1 online resource (219 p.)
Collana	Oxford scholarship online
Disciplina	615.1
Soggetti	Drugs - History Drugs - Design Pharmaceutical chemistry Electronic books.
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Previously issued in print: 2015.
Nota di bibliografia	Includes bibliographical references at the end of each chapters and index.
Nota di contenuto	Cover; Top Drugs History, Pharmacology, and Syntheses; Copyright; Dedication; Contents; Preface; Cardiovascular Drugs; Chapter 1: Atorvastatin Calcium (Lipitor); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 2: Clopidogrel Bisulfate (Plavix); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Bioavailability, Metabolism, and Toxicology; 2.2 Mechanism of Action; 2.3 Structure-Activity Relationship; 3 SYNTHESIS 3.1 Discovery Route3.2 Process Route; 3.3 Synthesis of Radio-labeled API; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 3: Amlodipine (Novasc); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Cancer Drugs; Chapter 4: Paclitaxel (Taxol); 1 HISTORY; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability,

Metabolism, and Toxicology; 3 PROCESS SEMI-SYNTHESIS; 4 TOTAL SYNTHESIS  
4.1 Holton's Synthesis 4.2 Nicolaou's Synthesis; 4.3 Danishefsky's Synthesis; 4.4 Wender's Synthesis; 5 CONCLUDING REMARKS; 6 REFERENCES; Chapter 5: Imatinib Mesylate (Gleevec); 1 HISTORY; 1.1 A Brief History of Cancer Drugs; 1.2 Treatments of Chronic Myeloid Leukemia; 1.3 Protein Kinase Inhibitors; 1.4 Genesis of Gleevec; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; Drugs for Metabolic Diseases Chapter 6: Sitagliptin (Januvia) 1 HISTORY OF DIABETES AND DIABETIC DRUGS; 1.1 Sulfonylureas; 1.2. Biguanides; 1.3 PPAR Agonists ; 2 PHARMACOLOGY; 2.1 Mechanism of Action ; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS; 3.1 Discovery Synthesis; 3.2 Process/Manufacturing Synthesis; 4 CONCLUDING REMARKS; 5 REFERENCES; CNS Drugs; Chapter 7: Duloxetine Hydrochloride (Cymbalta) ; 1 HISTORY OF DEPRESSION AND ANTIDEPRESSANTS; 1.1 Monoamine Oxidase Inhibitors; 1.2 Tricyclic Antidepressants; 1.3 Selective Serotonin Reuptake Inhibitors  
1.4 Serotonin and Norepinephrine Reuptake Inhibitors 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology ; 3 SYNTHESIS; 3.1 Discovery Route; 3.2 Process Route; 4 CONCLUDING REMARKS; 5 REFERENCES; Chapter 8: Olanzapine (Zyprexa) ; 1 HISTORY OF SCHIZOPHRENIA AND ANTIPSYCHOTIC DRUGS ; 1.1 Typical Antipsychotics-The First Generation; 1.2 Atypical Antipsychotics-The Second Generation; 2 PHARMACOLOGY; 2.1 Mechanism of Action; 2.2 Structure-Activity Relationship; 2.3 Bioavailability, Metabolism, and Toxicology; 3 SYNTHESIS  
3.1 Discovery Route

---

Sommario/riassunto

'Top Drugs' provides an in-depth study on ten prominent drugs, outlining the chemistry behind each one's creation. Jie Jack Li, a medicinal chemist and an expert on drug discovery, offers a thorough analysis of the landscape of current drug development. The comprehensive text is divided by health issues, including cardiovascular, cancer, metabolic diseases, and infectious diseases. Each section features individual chapters on significant drugs, outlining the chemistry and history of the drug's discovery.

---

2. Record Nr.	UNINA9910821233403321
Titolo	Sustainable operations management // guest editors, Professor Helen Walker [and three others]
Pubbl/distr/stampa	[Bradford, England] : , : Emerald, , 2014 ©2014
ISBN	1-78441-175-2
Descrizione fisica	1 online resource (168 p.)
Collana	International Journal of Operations & Production Management, , 0144-3577 ; ; Volume 34, Number 5
Disciplina	338.927
Soggetti	Sustainable development
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	"The official journal of the European Operations Management Association"--Cover.
Nota di bibliografia	Includes bibliographical references at the end of each chapters.
Nota di contenuto	Cover; Editorial board; Guest editorial; The diffusion of environmental management system and its effect on environmental management practices; The impact of environmental supply chain sustainability programs on shareholder wealth; Social sustainability in developing country suppliers; Supply chain collaboration and sustainability: a profile deviation analysis; Sustainable supply chains: a framework for environmental scanning practices; Reputational risks and sustainable supply chain management
Sommario/riassunto	Increasingly, organisations are interested in managing corporate social responsibility (CSR) and sustainability as part of their operations management (OM). OM practices and research must respond to demands to address sustainability. This response is triggered by climate change and other environmental concerns, the well-being of workers and communities, and other broad social demands. We define sustainable OM as the pursuit of social, economic and environmental objectives - the triple bottom line [TBL] - within operations of a specific firm and operational linkages that extend beyond the firm